Novavax is set to finally gain approval for its much-delayed COVID-19 vaccine, NVX-CoV2373, in key territories in early 2022, but doubts about its manufacturing and the Omicron variant are clouding its outlook.
The recombinant nanoparticle protein-based vaccine will be Novavax’s first ever product on the market and has produced strong trial data,...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
